{"title":"鼻口腔配方的生长和评估","authors":"Shweta Swamy, Dr. D. Nagendra Kumar","doi":"10.36713/epra15974","DOIUrl":null,"url":null,"abstract":"The invasive fungal infection requires a long treatment schedule; however, treatment becomes more cumbersome due to the development of resistance. Most anti-fungal moieties show systemic toxicity upon oral administration. Eberconazole (EBZ) is a BCS class II drug that has poor solubility and high permeability. Niosomes are vesicular carriers that can entrap both hydrophilic and lipophilic drugs. The formulation has shown 86 ± 0.85% entrapment efficiency while noisome appeared ring-like structure during its microscopic evaluation. Further evaluations of its in vitro and in vivo release studies will be performed in the future for its efficacy and anti-fungal activity. \nKEYWORDS: Eberconazole; niosomes; sustained release; anti-fungal","PeriodicalId":114964,"journal":{"name":"EPRA International Journal of Research & Development (IJRD)","volume":"138 50","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"GROWTH AND ASSESSMENT OF NIOSOMAL FORMULATIONS\",\"authors\":\"Shweta Swamy, Dr. D. Nagendra Kumar\",\"doi\":\"10.36713/epra15974\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The invasive fungal infection requires a long treatment schedule; however, treatment becomes more cumbersome due to the development of resistance. Most anti-fungal moieties show systemic toxicity upon oral administration. Eberconazole (EBZ) is a BCS class II drug that has poor solubility and high permeability. Niosomes are vesicular carriers that can entrap both hydrophilic and lipophilic drugs. The formulation has shown 86 ± 0.85% entrapment efficiency while noisome appeared ring-like structure during its microscopic evaluation. Further evaluations of its in vitro and in vivo release studies will be performed in the future for its efficacy and anti-fungal activity. \\nKEYWORDS: Eberconazole; niosomes; sustained release; anti-fungal\",\"PeriodicalId\":114964,\"journal\":{\"name\":\"EPRA International Journal of Research & Development (IJRD)\",\"volume\":\"138 50\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EPRA International Journal of Research & Development (IJRD)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36713/epra15974\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EPRA International Journal of Research & Development (IJRD)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36713/epra15974","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
侵袭性真菌感染需要长时间的治疗，但由于抗药性的产生，治疗变得更加麻烦。大多数抗真菌药物口服后会出现全身毒性。依柏康唑（EBZ）是一种 BCS II 类药物，溶解性差，渗透性高。Niosomes 是一种囊状载体，既能吸附亲水性药物，也能吸附亲脂性药物。该制剂的夹持效率为 86 ± 0.85%，而在显微镜评估中，noisome 呈环状结构。今后还将对其体外和体内释放研究进行进一步评估，以确定其药效和抗真菌活性。关键词： 依柏康唑；niosomes；缓释；抗真菌
The invasive fungal infection requires a long treatment schedule; however, treatment becomes more cumbersome due to the development of resistance. Most anti-fungal moieties show systemic toxicity upon oral administration. Eberconazole (EBZ) is a BCS class II drug that has poor solubility and high permeability. Niosomes are vesicular carriers that can entrap both hydrophilic and lipophilic drugs. The formulation has shown 86 ± 0.85% entrapment efficiency while noisome appeared ring-like structure during its microscopic evaluation. Further evaluations of its in vitro and in vivo release studies will be performed in the future for its efficacy and anti-fungal activity.
KEYWORDS: Eberconazole; niosomes; sustained release; anti-fungal
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
